Locations
New York, NY, USA · Boston, MA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2019
Elevation Oncology is dedicated to the discovery and development of selective cancer therapies targeting solid tumors with significant unmet medical needs. The company focuses on innovative approaches to drug development, particularly through its differentiated antibody-drug conjugates (ADCs) like EO-3021, which targets Claudin 18.2. Elevation's unique strategy involves matching therapies to patients' specific tumor characteristics, thereby enhancing treatment efficacy. With a robust pipeline and ongoing clinical trials, including the Phase 1 study for EO-3021, Elevation Oncology is positioned to make a meaningful impact in the oncology market, addressing critical gaps in cancer treatment.
Something looks off?